Kapspargo Sprinkle

(Metoprolol Succinate)

ApprovedSmall molecule

Kapspargo Sprinkle is a small molecule that works as a Beta-1 Adrenergic Receptor Antagonist.[2] It is being used across 11 indications, with its most advanced program in Approved.[1]

Kapspargo Sprinkle is one of 284 small molecule programs targeting Angina Pectoris. It is currently in Approved.

Indications

Total Trials

Active Trials

283

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Angina PectorisUnknown

Congestive Heart FailureUnknown

StrokeUnknown

Heart DiseaseActive, not recruiting

Heart Failure With Reduced Ejection FractionRecruiting

Oxidative StressActive, not recruiting

EffectivenessTerminated

Myocardial InfarctionActive, not recruiting

CardiomyopathyRecruiting

Mitral RegurgitationCompleted

Angina PectorisPreclinical

Unknown

Congestive Heart FailurePreclinical

Unknown

StrokePreclinical

Unknown

Heart DiseasePreclinical

Active, not recruiting

Heart Failure With Reduced Ejection FractionApproved

Recruiting

Oxidative StressApproved

Active, not recruiting

EffectivenessPreclinical

Terminated

Myocardial InfarctionApproved

Active, not recruiting

CardiomyopathyPhase 3

Recruiting

Mitral RegurgitationApproved

Completed

Showing 10 of 11 indications

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Kapspargo Sprinkle

BBp Consulting, Inc

Approved

1 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Activella

Tricor

1 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 9

Glucocorticoid

AbbVie

Preclinical

1 10

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Not yet recruiting

Heart Failure

NCT04996550

Phase 3Recruiting

Cardiovascular

NCT05931276

Q3 2029

ApprovedRecruiting

Heart Failure With Reduced Ejection Fraction

NCT07490067

Q3 2031

Post-ApprovalRecruiting

Heart Failure

NCT06964464

Q4 2035

Post-ApprovalActive, not recruiting

Myocardial Infarction

NCT03778554

Clinical

Trials by Indication[1]

Hypertension6 trials

BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF

Completed·UUniversity of Pennsylvania·Phase 4·NCT04434664·50 enrolled

Black Education and Treatment of Hypertension (BEAT HTN)

Completed·—·Phase 4·NCT00661895·99 enrolled

COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension

Completed· GSK logo

GSK·Phase 3·NCT00273052·514 enrolled

Show 3 more trials

A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT01970059·302 enrolled

Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02242812·24 enrolled

Sympathetic Nervous System Modulation in Hypertension

Terminated·UUniversity of Cincinnati·Phase 4·NCT00491387·24 enrolled

Hypertensive5 trials

Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?

Terminated·MMayo Clinic·Phase 4·NCT01605370·1 enrolled

Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT01501929·32 enrolled

307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00255502·100 enrolled

Show 2 more trials

Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00255528·144 enrolled

Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT01502787·46 enrolled

Heart Failure5 trials

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00391846·252 enrolled

Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure

Terminated· Gilead logo

Gilead·Phase 3·NCT00077948·175 enrolled

Are Carvedilol and Metoprolol Succinate Comparable Treatments in Heart Failure Patients With Reduced Ejection Fraction

Not yet recruiting·OOdense University Hospital··NCT04996550·5,600 enrolled

Show 2 more trials

A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT02012075·316 enrolled

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

Recruiting·UUniversity of Rochester·Phase 4·NCT06964464·2,000 enrolled

Cardiomyopathy2 trials

The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.

Completed·SSteen Hvitfeldt Poulsen·Phase 2·NCT03532802·30 enrolled

The Efficacy and Safety of Metoprolol as add-on Treatment to Standard of Care in Preventing Cardiomyopathy in Patients With DMD

Recruiting·MMedical University of Gdansk·Phase 3·NCT05066633·150 enrolled

Myocardial Infarction2 trials

Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction

Active, not recruiting·—·Phase 4·NCT03778554·2,760 enrolled

Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)

Active, not recruiting·KKarolinska Institutet·Phase 4·NCT03278509·5,000 enrolled

23 more indications

Efficacy and Safety2 trials

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

Completed·CCytokinetics·Phase 3·NCT05767346·175 enrolled

Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate

Completed·SSumitomo Pharma (Suzhou) Co., Ltd.·Phase 4·NCT02612298·198 enrolled

Gene Expression1 trial

Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart

Completed·UUniversity of Colorado, Denver·Phase 4·NCT01798992·56 enrolled

Endothelial Function1 trial

Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function

Completed·BBerlin-Chemie AG Menarini Group·Phase 4·NCT01248338·80 enrolled

Hemodialysis1 trial

Evaluation of Metoprolol Pharmacokinetics in Patients Receiving Hi Flux Hemodialysis

Completed·UUniversity of Michigan··NCT03612180·8 enrolled

Atrial Fibrillation1 trial

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

Completed·AARCA Biopharma, Inc.·Phase 2·NCT01970501·267 enrolled

Oxidative Stress1 trial

Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells

Completed·EEmory University·Phase 4·NCT01041287·96 enrolled

Mitral regurgitation1 trial

A Randomized Clinical Trial of Metoprolol in Participants With Mitral Regurgitation.

Completed·MMayo Clinic·Phase 4·NCT00166400·60 enrolled

Peripheral Arterial Disease1 trial

Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure

Completed·TThomas Jefferson University·Phase 3·NCT01499134·17 enrolled

Cardiac Dysfunction1 trial

Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)

Completed·UUniversity of Alabama at Birmingham·Phase 2/3·NCT01052428·38 enrolled

Heart1 trial

A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate

Completed·SSaniona·Phase 1·NCT03488719·37 enrolled

MPA1 trial

Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, Compared to Metoprolol Succinate and Placebo in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02264002·119 enrolled

Heart Disease1 trial

Metoprolol and Trimetazidine for Coronary Heart Disease With Angina

Completed·SShiyan City Renmin Hospital·N/A·NCT07074834·102 enrolled

Hypotensive Anesthesia1 trial

Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries

Recruiting·—·Phase 4·NCT04914234·60 enrolled

Fasting Conditions1 trial

Bioequivalence Study of Metoprolol Succinate ER Tablets, 200 mg Under Fasting Conditions

Completed·—·Phase 1·NCT01673997·48 enrolled

Cirrhosis1 trial

Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis

Completed·UUniversity of Sao Paulo·Phase 3·NCT01676285·125 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Terminated·UUniversity of Minnesota·Phase 3·NCT02587351·532 enrolled

Effectiveness1 trial

Pharmacogenetic Prediction of Metoprolol Effectiveness

Terminated·UUniversity of Colorado, Denver·N/A·NCT02293096·462 enrolled

Tachycardia1 trial

Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study

Terminated·HHackensack Meridian Health·Phase 1·NCT05096884·14 enrolled

Cardiovascular1 trial

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

Recruiting·VVA Office of Research and Development·Phase 3·NCT05931276·2,540 enrolled

Quality of Life1 trial

The Impact of Nebivolol Versus Metoprolol on Quality of Life

Terminated·—·N/A·NCT01441570·11 enrolled

COVID-191 trial

Medicine-induced Cardiac Hemodialysis on COVID-19

Completed·YYang I. Pachankis·Phase 4·NCT05711810·1 enrolled

Heart Failure With Reduced Ejection Fraction1 trial

Personalizing Heart Failure Treatment With Genomics: A Clinical Trial to Understand the Mechanisms and Validate a Polygenic Risk Score for Beta-Blocker Response

Recruiting·UUniversity of Michigan·Approved·NCT07490067·100 enrolled

Unspecified3 trials

Weak Pulse at Yang and Wiry Pulse at Yin Theory

Completed·XXikun Li·N/A·NCT07378228·70 enrolled

Factorial Study of Metoprolol Succinate TOPROL-XL (324A)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00642096·1,900 enrolled

Bioequivalence Study for Metoprolol Succinate ER Tablets 50 mg Under Fasting Condition

Completed·—·Phase 1·NCT01694797·48 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

LOPRESSOR

NDA NDA017963

Mar 30, 1984

LOPRESSOR

NDA NDA018704

Dec 27, 1989

LOPRESSOR

NDA NDA019786

Feb 5, 2001

TOPROL-XL

NDA NDA019962

Jan 26, 2018

KAPSPARGO SPRINKLE

NDA NDA210428

Apr 10, 2025

LOPRESSOR

NDA NDA219373

Aug 28, 2025

LOPRESSOR

NDA NDA218698

Sources

References

[1]
ClinicalTrials.gov — 46 trial records for Metoprolol Succinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metoprolol Succinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metoprolol Succinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA218698). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Bp Consulting, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Beta-1 Adrenergic Receptor Antagonist[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: BBp Consulting, Inc

Kapspargo Sprinkle

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q3 2029

Q3 2031

Q4 2035

Trials by Indication[1]

Hypertension6 trials

Hypertensive5 trials

Heart Failure5 trials

Cardiomyopathy2 trials

Myocardial Infarction2 trials

Efficacy and Safety2 trials

Gene Expression1 trial

Endothelial Function1 trial

Hemodialysis1 trial

Atrial Fibrillation1 trial

Oxidative Stress1 trial

Mitral regurgitation1 trial

Peripheral Arterial Disease1 trial

Cardiac Dysfunction1 trial

Heart1 trial

MPA1 trial

Heart Disease1 trial

Hypotensive Anesthesia1 trial

Fasting Conditions1 trial

Cirrhosis1 trial

Chronic Obstructive Pulmonary Disease1 trial

Effectiveness1 trial

Tachycardia1 trial

Cardiovascular1 trial

Quality of Life1 trial

COVID-191 trial

Heart Failure With Reduced Ejection Fraction1 trial

Unspecified3 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News